US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 January 2015 The US Food and Drug Administration has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.
5 January 2015 The US Food and Drug Administration has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.
5 January 2015 The US Food and Drug Administration has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.